Cargando…

Efficacy and safety of cytokines versus first-line sunitinib and second-line axitinib for patients with metastatic renal cell carcinoma (ESCAPE study): A study protocol for phase III randomized sequential open-label study

Appropriate protocol for the sequential treatment of metastatic renal cell carcinoma (mRCC) has not been established yet. Some mRCC cases with favorable risk were reported to achieve complete remission and durable response using interferon alfa (IFNα) + low dose interleukin-2 (IL-2). Cytokine therap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kadono, Yoshifumi, Konaka, Hiroyuki, Izumi, Kouji, Anai, Satoshi, Fujimoto, Kiyohide, Ishibashi, Kei, Kawai, Noriyasu, Kato, Taku, Iba, Akinori, Masumori, Naoya, Yoshimura, Kenichi, Mizokami, Atsushiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610625/ https://www.ncbi.nlm.nih.gov/pubmed/31312749 http://dx.doi.org/10.1016/j.conctc.2019.100403

Ejemplares similares

Efficacy and Safety of First-Line Cytokines versus Sunitinib and Second-Line Axitinib for Patients with Metastatic Renal Cell Carcinoma (ESCAPE Study): A Phase III, Randomized, Sequential Open-Label Study
por: Kadono, Yoshifumi, et al.
Publicado: (2023)

Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
por: Géczi, Lajos, et al.
Publicado: (2020)

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
por: Tamada, Satoshi, et al.
Publicado: (2021)

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
por: Machioka, Kazuaki, et al.
Publicado: (2018)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

Testosterone and Bone Health in Men: A Narrative Review
por: Shigehara, Kazuyoshi, et al.
Publicado: (2021)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
por: Lu, Peiyao, et al.
Publicado: (2020)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
por: Numakura, Kazuyuki, et al.
Publicado: (2021)

Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial
por: Izumi, Kouji, et al.
Publicado: (2017)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
por: Facchini, Gaetano, et al.
Publicado: (2019)

Relation between athletic club affiliation from school age and future serum free testosterone levels in Japan: A cross‐sectional study
por: Kato, Yuki, et al.
Publicado: (2023)

Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors
por: Tamada, Satoshi, et al.
Publicado: (2018)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan
por: Kitagawa, Yasuhide, et al.
Publicado: (2014)

A case of adrenal lymphangioma resected laparoscopically with minimal invasiveness
por: Yaegashi, Hiroshi, et al.
Publicado: (2020)

Comparison of the Prognostic Value of Inflammatory and Nutritional Indices in Nonmetastatic Renal Cell Carcinoma
por: Makino, Tomoyuki, et al.
Publicado: (2023)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian “Real-World” SAX Study
por: D'Aniello, Carmine, et al.
Publicado: (2016)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
por: Choueiri, T. K., et al.
Publicado: (2020)

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
por: Juengel, Eva, et al.
Publicado: (2021)

Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review
por: Kadomoto, Suguru, et al.
Publicado: (2020)

Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy
por: Shigehara, Kazuyoshi, et al.
Publicado: (2020)

Efficacy of keishibukuryogan for hot flashes in prostate cancer patients receiving androgen deprivation therapy: a sub-analysis focusing on hormonal and cytokine levels
por: Shigehara, Kazuyoshi, et al.
Publicado: (2023)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
por: Cai, Wen, et al.
Publicado: (2019)

Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report
por: Yaegashi, Hiroshi, et al.
Publicado: (2015)

Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study)
por: Izumi, Kouji, et al.
Publicado: (2021)

Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer
por: Toriumi, Ren, et al.
Publicado: (2022)

Impact of Pelvic Anatomical Changes Caused by Radical Prostatectomy
por: Kadono, Yoshifumi, et al.
Publicado: (2022)

Phase II study of sunitinib as second-line treatment for advanced gastric cancer
por: Bang, Yung-Jue, et al.
Publicado: (2010)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
por: Murata, Masaki, et al.
Publicado: (2019)

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
por: Nishimoto, Koshiro, et al.
Publicado: (2022)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
por: Bæk Møller, Nanna, et al.
Publicado: (2019)

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
por: Bilen, Mehmet A., et al.
Publicado: (2022)

Human papillomavirus 16–positive penile Bowen’s disease involving the distal urethra: A case report
por: Sakamoto, Jiro, et al.
Publicado: (2020)

A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age
por: Iwamoto, Hiroaki, et al.
Publicado: (2020)

Risk Factors Affecting Decreased Libido Among Middle-Aged to Elderly Men; Nocturnal Voiding is an Independent Risk Factor of Decreased Libido
por: Shigehara, Kazuyoshi, et al.
Publicado: (2021)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
por: Yoshida, Tsukasa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ljme7089mj34ro53q30jat4ni7